Abstract
The brain is a complex, regulated organ with a highly controlled access mechanism: The Blood-Brain Barrier (BBB). The selectivity of this barrier is a double-edged sword, being both its greatest strength and weakness. This weakness is evident when trying to target therapeutics against diseases within the brain. Diseases such as metastatic brain cancer have extremely poor prognosis due to the poor permeability of many therapeutics across the BBB. Peptides can be designed to target BBB receptors and gain access to the brain by transcytosis. These peptides (known as BBB-shuttles) can carry compounds, usually excluded from the brain, across the BBB. BBB-shuttles are limited by poor loading of therapeutics and degradation of the peptide and cargo. Likewise, nano- submicro- and microparticles can be fine-tuned to limit their degradation and with high loading of therapeutics. However, most nano- and microparticles’ core materials completely lack efficient targeting, with a few selected materials able to cross the BBB passively. Combining the selectivity of peptides with the high loading potential of nano-, microparticles offers an exciting strategy to develop novel, targeted therapeutics towards many brain disorders and diseases. Nevertheless, at present the field is diverse, in both scope and nomenclature, often with competing or contradictory names. In this review, we will try to address some of these issues and evaluate the current state of peptide mediated nano,-microparticle transport to the brain, analyzing delivery vehicle type and peptide design, the two key components that must act synergistically for optimal therapeutic impact.
Keywords: Nanoparticles, submicroparticles, peptides, BBB-shuttles, iron oxide, gold, blood-brain barrier, nanoconstruct.
Current Pharmaceutical Design
Title:Peptide Mediated Brain Delivery of Nano- and Submicroparticles: A Synergistic Approach
Volume: 24 Issue: 13
Author(s): Mark McCully, Macarena Sanchez-Navarro , Meritxell Teixido*Ernest Giralt*
Affiliation:
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona,Spain
- Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology (BIST), Barcelona,Spain
Keywords: Nanoparticles, submicroparticles, peptides, BBB-shuttles, iron oxide, gold, blood-brain barrier, nanoconstruct.
Abstract: The brain is a complex, regulated organ with a highly controlled access mechanism: The Blood-Brain Barrier (BBB). The selectivity of this barrier is a double-edged sword, being both its greatest strength and weakness. This weakness is evident when trying to target therapeutics against diseases within the brain. Diseases such as metastatic brain cancer have extremely poor prognosis due to the poor permeability of many therapeutics across the BBB. Peptides can be designed to target BBB receptors and gain access to the brain by transcytosis. These peptides (known as BBB-shuttles) can carry compounds, usually excluded from the brain, across the BBB. BBB-shuttles are limited by poor loading of therapeutics and degradation of the peptide and cargo. Likewise, nano- submicro- and microparticles can be fine-tuned to limit their degradation and with high loading of therapeutics. However, most nano- and microparticles’ core materials completely lack efficient targeting, with a few selected materials able to cross the BBB passively. Combining the selectivity of peptides with the high loading potential of nano-, microparticles offers an exciting strategy to develop novel, targeted therapeutics towards many brain disorders and diseases. Nevertheless, at present the field is diverse, in both scope and nomenclature, often with competing or contradictory names. In this review, we will try to address some of these issues and evaluate the current state of peptide mediated nano,-microparticle transport to the brain, analyzing delivery vehicle type and peptide design, the two key components that must act synergistically for optimal therapeutic impact.
Export Options
About this article
Cite this article as:
McCully Mark , Sanchez-Navarro Macarena, Teixido Meritxell *, Giralt Ernest *, Peptide Mediated Brain Delivery of Nano- and Submicroparticles: A Synergistic Approach, Current Pharmaceutical Design 2018; 24 (13) . https://dx.doi.org/10.2174/1381612824666171201115126
DOI https://dx.doi.org/10.2174/1381612824666171201115126 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Interference of Metals and Medications with the Detection of Lipid Peroxidation in Humans by Photometric TBARS Assay
Current Analytical Chemistry Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews State-of-the-Art Magnetic Resonance Spectroscopy in Oncologic Imaging
Current Molecular Imaging (Discontinued) Analysis of HIV Tropism in Ugandan Infants
Current HIV Research Novel Pharmacologic Approaches to the Management of Sepsis: Targeting the Host Inflammatory Response
Recent Patents on Inflammation & Allergy Drug Discovery A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery
Recent Patents on Nanotechnology Oiling the Pipeline: The Path from Genomics to Drug Discovery for Brain Disease
Current Drug Targets - CNS & Neurological Disorders Alternative Use of Bisphosphonate Therapy for Rheumatic Disease
Current Pharmaceutical Design All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Herbal Phytochemicals as Immunomodulators
Current Immunology Reviews (Discontinued) Heme Oxygenase-1 in Lung Disease
Current Drug Targets Biologics for Extraintestinal Manifestations of IBD
Current Drug Targets Identification of Two Novel Mutations in the <i>ATM</i> Gene from Patients with Ataxia-Telangiectasia by Whole Exome Sequencing
Current Genomics Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Current Cancer Drug Targets Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy The Double Roles of the Prostaglandin E<sub>2</sub> EP2 Receptor in Intracerebral Hemorrhage
Current Drug Targets Current Advances in Vehicles for Brain Gene Delivery
Current Gene Therapy Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Current Molecular Medicine Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Current Progress in the Development of HIV Vaccines
Current Pharmaceutical Design